The Medicines Co. (MDCO) and Roche AG unit Hoffmann-Laroche Inc. are joining the effort launched by the Office of the Assistant Secretary for Preparedness and Response, through the Biomedical Advanced Research and Development Authority (BARDA), to develop products to combat the emerging threat of multidrug-resistant bacterial infections, often referred to as superbugs.